Patient Support

shoe image

Patient support

The patient education tools below may be downloaded for immediate use.

If you would like to order these materials for your office, please contact your Sales Representative or call 1-800-223-1062 to request a Sales Representative visit.

To download the materials, you will need Adobe Reader. Download the Free Adobe Reader now.

Link to Adobe Reader download page
Picture of two identical patient brochures

Overview of osteoarthritis with frequently asked questions about HYALGAN®

  • Features an anatomical drawing of the knee before and after onset of osteoarthritis.
  • Summarizes the available prescription and over-the-counter treatment options.

Link to download a printable version of the Patient BrochureDownload a printable version of the Patient Brochure.





Action TrackerSM

A daily diary that provides patients with a place to keep track of their injection schedule and osteoarthritis knee pain, and to record health care professional appointments, medications used to relieve osteoarthritis pain, and changes in activity level.

Link to download a printable version of the Action TrackerDownload a printable version of the Action TrackerSM

Important Safety Information for HYALGAN®

  • HYALGAN® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpha-rmacologic therapy, and to simple analgesics, eg, acetaminophen
  • HYALGAN® is contraindicated in patients with known hypersensitivity to hyaluronate preparations. Intra-articular injections are contraindicated in cases of past and present infections or skin diseases in the area of the injection site
  • The effectiveness of a single treatment cycle of less than 3 injections has not been established
  • In the US clinical trial of 495 patients, the only adverse event showing statistical significance vs placebo was injection-site pain
  • Other adverse events included gastrointestinal complaints, headache, local ecchymosis and rash, local joint pain and swelling, and local pruritus. However, the incidence of these events was similar in the HYALGAN®-treated and placebo groups
  • In other clinical studies, the frequency and severity of adverse events occurring during repeat treatment cycles did not increase over that reported for a single treatment cycle

Click here for additional important information for HYALGAN®.